Although visfatin is presently the focus of intense study, to date, many of the current findings show inconsistencies with regard to visfatins role in the pathogenesis of obesity-mediated T2DM and the metabolic syndrome. This evidence concerns the gene NAMPT and obesity due to melanocortin 4 receptor deficiency.